InterVenn Biosciences Receives Key AMA Code for Non-Invasive Ovarian Cancer Test

InterVenn Biosciences, a precision diagnostics company focused on liquid biopsy through glycoproteomics, has announced that its flagship test, GlycoKnow™ Ovarian, has been assigned a Proprietary Laboratory Analysis (PLA) code by the American Medical Association (AMA). This development is a key step in making the blood-based diagnostic test more accessible and commercially viable. GlycoKnow Ovarian is designed to differentiate between cancerous and benign pelvic masses, helping women receive timely and appropriate care. The test will be available commercially starting in the fall, with the PLA code effective from October 1, 2025. This is InterVenn’s first commercial test in the women’s health sector. The PLA code provides a standardized billing mechanism and opens the door for potential insurance reimbursement, which is essential for broader clinical adoption. The code also signifies that the test is ready for integration into routine medical practice. Andrew Quong, CEO of InterVenn, highlighted the importance of the PLA code. “This milestone makes our advanced diagnostic more accessible to women who need it most. By offering a clear and standardized way for healthcare providers to access the test, we are accelerating its adoption across the U.S. healthcare system and improving patient access to this critical innovation,” he said. Quong added that GlycoKnow Ovarian serves as a precise, non-invasive tool to aid clinicians in making informed decisions when a pelvic mass is detected, ultimately streamlining the diagnostic process for women. Ovarian cancer remains a major challenge in women’s health, with many patients undergoing unnecessary procedures that can impact their overall care experience and quality of life. InterVenn’s test uses AI and glycoproteomics to analyze blood samples, offering physicians a more accurate assessment of a patient’s condition and supporting better treatment planning. David Crotzer, M.D., a gynecologic oncologist at Methodist Estabrook Cancer Center and Clinical Assistant Professor at Creighton University, emphasized the importance of the test. “Up to 80% of pelvic masses are benign, so it’s vital to determine which women are at risk for ovarian cancer and which are not. This non-invasive test will improve our confidence in decision-making and ensure that women with cancer receive timely care, while those with benign masses avoid unnecessary surgeries and treatments. It’s a meaningful advancement for patients, providers, and the healthcare system.” InterVenn Biosciences focuses on decoding the human glycoproteome to unlock biological insights that support personalized, predictive, and preventative care. The company has developed a proprietary platform called GlycoVision™, which combines AI and machine learning to analyze glycoproteomic data at a clinically relevant scale. InterVenn collaborates with patients, physicians, researchers, and biopharma organizations to explore the role of glycoproteins in health and disease. Its insights help guide decisions on disease detection, treatment, and research. For more information about GlycoKnow Ovarian or to join the early access program, visit www.intervenn.com.